Pharming Group NV Sponsored ADR PHAR 深 滬
已收盤 02-06 16:00:00 美东时间
16.09
+0.050
+0.31%
華盛通- 最 高16.45
- 今 開16.10
- 成交量 3.80万股
- 最 低 15.96
- 昨 收 16.04
- 總市值 11.21亿
- 52周最高 21.34
- 市盈率 靜 --
- 換手率 0.05%
- 52周最低 7.5018
- 委 比 -49.25%
- 總股本 6966.88万
- 歷史最高 21.99
- 量 比 0.66
- 振 幅 3.05%
- 歷史最低 6.10
- 每 手 1
- 風險率 3.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Pharming Group Expects 2026 Revenue At $405-$425 Mln
BRIEF-Pharming Group Expects 2026 Revenue At $405-$425 Mln Feb 3 (Reuters) - Pharming Group NV PHAR.AS : ANNOUNCES 2026 FINANCIAL GUIDANCE AND HIGHLIGHTS RARE DISEASE PIPELINE AT INVESTOR DAY 2026 REVENUE GUIDANCE OF $405-$425 MILLION 2026 OPERATING EXPENSE GUIDANCE OF $330-$335 MILLION Source text:
02-03 14:09
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Vyome Holdings (NASDAQ:HIND) stock increased by 16.1% to $2.23 during ...
02-02 20:05
Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS
Pharming Group received a Complete Response Letter (CRL) from the FDA regarding its sNDA for Joenja® to treat APDS in children aged 4-11. The FDA raised concerns about potential underexposure in lower weight pediatric patients and issues with an analytical method used in production batch testing. The company plans to address these concerns, request a Type A meeting, and resubmit the application. Joenja remains approved for APDS in patients aged 1...
02-01 20:17
Pharming Group reports preliminary 2025 revenues and announces Investor Day
Pharming Group N.V. reported preliminary 2025 revenues of approximately $376 million, exceeding expectations and reflecting strong demand for RUCONEST® and Joenja®. The company plans a virtual Investor Day on February 3, 2026, to discuss its advancing clinical pipeline, including leniolisib for immune dysregulation and KL1333 for mitochondrial diseases, alongside 2026 financial guidance. CEO Fabrice Chouraqui highlighted continued growth and stra...
01-08 06:00
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining aroun...
2025-12-15 21:06
Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit
Pharming Group N.V. announced its participation in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025, in New York City. Anurag Relan, M.D., Chief Medical Officer of Pharming, will discuss the hereditary angioedema (HAE) market in a fireside chat at 1:50 pm ET / 19:50 CET. The company, dedicated to transforming lives of patients with rare diseases, is inviting one-on-one meetings with its management team. For more information, con...
2025-12-08 07:00
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Kazia Therapeutics (NASDAQ:KZIA) shares increased by 51.6% to $8.73 du...
2025-11-19 20:05
Pharming Group shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
Pharming Group shares are trading higher after the company reported better-than...
2025-11-06 21:52
Pharming Raises FY2025 Sales Guidance from $335.000M-$350.000M to $365.000M-$375.000M vs $339.625M Est
Pharming (NASDAQ:PHAR) raises FY2025 sales outlook from $335.000 million-$350.000 million to $365.000 million-$375.000 million vs $339.625 million estimate.
2025-11-06 16:19
Pharming Q3 EPS $0.10 Beats $(0.00) Estimate, Sales $97.300M Beat $93.430M Estimate
Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $(0.00) by 10100 percent. This is a 600 percent increase over losses of $(0.02) per share from the same
2025-11-06 14:07
